The Role of Vaccines in the Fight Against Antimicrobial Resistance

Dr. Mateusz Hasso-Agopsowicz

Technical Officer, Department of Immunization, Vaccines & Biologicals, World Health Organization

ESCAIDE, November 2025

The burden of AMR

- AMR is a global health threat **4.71 million deaths associated** with bacterial AMR worldwide in 2021;
- The **three leading pathogens** with the highest burden caused with 2.3 million deaths associated with AMR in 2021: *S. pneumoniae*, *S. aureus*, and *E.coli*



https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01867-1/fulltext

How do vaccines reduce AMR?

- Vaccines prevent infections with drug-susceptible and resistant pathogens
- Vaccines prevent individuals and communities from getting sick
- Decrease antibiotic use (causal chain)
- Suppress resistance evolution and decrease transmission of resistant pathogens (causal chain)



WHEN to evaluate the role of vaccines in reducing AMR?

OPPORTUNITIES TO CONSIDER VACCINE IMPACT ON AMR

Early Development → Advanced Clinical Development → Regulatory Approval → Policy Decision → Gavi Vaccine Investment → Vaccine Assessment in Countries → Post-licensure Evaluation

EXAMPLES WHEN THE ROLE OF VACCINES ON AMR WAS CONSIDERED

N. Gonorrhea *K. pneumoniae*	RSV Influenza *S. pneumoniae*	Multiple	*S. typhi*	*Vaccines in VIS 2018 and 2024*	*S. pneumoniae*	*S. typhi* *S. pneumoniae*

Vaccines in National Action Plans Against AMR

Desk review of National Action Plans

MAJOR GAP: TO WHAT EXTENT CAN VACCINES REDUCE AMR?



CONTEXT

National Action Plans on AMR are countries' strategies to reduce AMR

METHOD

Desk review of 77 NAPs to measure how many NAPs integrate vaccines as interventions to reduce AMR

RESULT

67 NAPs (87%) mention vaccines, but only 33 (43%) have developed indicators to capture the role of vaccines against AMR;
10 NAPS do not mention vaccines

INTERPRETATION

Some understanding of the role of vaccines in reducing AMR- but it doesn't translate to action and integration with other AMR interventions

https://globalizationandhealth.biomedcentral.com/articles/10.1186/s12992-022-00878-6

WHO report: Estimating the impact of vaccines in reducing antimicrobial resistance and use

WHO has modelled the impact of vaccines against **24 pathogens** and found that vaccines have the potential to annually avert up to:

- **515,000 deaths**
- **28 million DALYs**
- **US $30 billion in hospital costs**
- **US $20 billion in productivity losses**

Which are all associated with AMR

These vaccines could also help to reduce antibiotic use by **2.5 billion doses**



AMR, antimicrobial resistance; DALY, disability-adjusted life years

The potential impact of vaccines on averting deaths associated with AMR

Vaccines have the potential to **avert** up to

515 000 deaths

associated with AMR annually– 32% in AFRO




Original research · 6 July 2023 · Open access

Request permissions · Cite this article · Share · Download PDF

Global and regional burden of attributable and associated bacterial antimicrobial resistance avertable by vaccination: modelling study

Author affiliations · Chaelin Kim [1], Marianne Holm [2], Isabel Frost [3], Mateusz Hasso-Agopsowicz [3], Kaja Abbas [4].

The potential impact of vaccines on averting antibiotic use

Vaccines have the potential to **avert** up to

2.5 billion

of defined daily **doses of antibotics** annually – 22% of the evaluated burden – 40% in SEARO



The potential impact of vaccines on averting hospital costs associated with AMR

Vaccines have the potential to **avert** up to

US $ 30 billion

in hospital costs associated with treating resistant infections annually – 30% in AMRO




Original research · 19 June 2025 · Open access Request permissions Cite this article Share Download PDF

The global economic burden of antibiotic-resistant infections and the potential impact of bacterial vaccines: a modelling study

Author affiliations · Nichola R Naylor [1 2], Mateusz Hasso-Agopsowicz [3], Chaelin Kim [4], Yixuan Ma [5], Isabel Frost [3], Kaja Abbas [4 6 7 8], ... Show all authors

Additional Resources

Mycobacterium tuberculosis (TB_2)

A vaccine against pulmonary *M.tuberculosis* disease given to 70% of children aged 10 years, with 10-year efficacy of 50% and subsequent boosting to ensure lifelong protection [TB_2]

Target pathogen:	Targeting:	Duration:	Usage scenario:	WHO AMR priority
Mycobacterium tuberculosis	Children aged 10 years	10 years	Efficacy: 50% Coverage: 70%	CRITICAL
Vaccine name: TB_2				Feasibility of vaccine development and implementation: HIGH

AMR health burden

WHO region	Deaths associated with resistance in 2019 (95% UI)	Deaths associated with resistance averted by a vaccine in 2019 (95% UI)	DALYs associated with resistance in 2019 (95% UI)	DALYs associated with resistance averted by a vaccine in 2019 (95% UI)
AFR	43 000 (39 000–48 000)	13 500 (12 000–15 500)	1.9 (1.7–2.1) million	521 000 (455 000–595 000)
EUR	12 000 (11 000–13 000)	4098 (3614–4656)	504 000 (466 000–545 000)	170 000 (153 000–191 000)
EMR	19 500 (17 000–22 500)	6015 (5137–7222)	899 000 (776 000–1 million)	252 000 (206 000–308 000)
SEAR	116 000 (98 000–134 000)	40 000 (33 500–48 000)	4.1 (3.5–4.9) million	1.4 (1.2–1.7) million
AMR	2508 (2224–2829)	858 (733–995)	88 000 (78 000–99 500)	29 000 (25 000–33 500)
WPR	18 500 (16 500–21 000)	6380 (5600–7347)	632 000 (570 000–700 000)	209 000 (187 000–239 000)
GLOBAL	**211 000** (193 000–231 000)	**70 500** (64 000–78 000)	**8.1** (7.5–8.9) **million**	**2.6** (2.3–2.8) **million**

Antibiotic use

WHO region	Pathogen-associated antibiotic use in 2019, DDD (95% UI)	Pathogen-associated antibiotic use averted by a vaccine in 2019, DDD (95% UI)
AFR	690 (670–700) million	230 (220–230) million
EUR	150 (150–160) million	52 (50–53) million
EMR	260 (250–270) million	84 (81–85) million
SEAR	1600 (1500–1600) million	520 (500–550) million
AMR	120 (120–120) million	42 (41–42) million
WPR	700 (680–720) million	240 (230–240) million
GLOBAL	**3500** (3400–3500) **million**	**1200** (1100–1200) **million**

AMR economic burden

WHO region	Hospital costs associated with resistance in 2019, US dollars (95% UI)	Hospital costs associated with resistance averted by a vaccine in 2019, US dollars (95% UI)	Productivity losses associated with resistance in 2019, US dollars	Productivity losses associated with resistance averted by a vaccine in 2019, US dollars
AFR	32.2 (17.2–60.3) million	9.8 (5.2–18.4) million	451 million	133 million
EUR	1399 (690–2648) million	480 (237–909) million	824 million	280 million
EMR	49.7 (23.5–89.6) million	16 (7.5–28.5) million	459 million	136 million
SEAR	243 (25.2–734) million	83.2 (8.6–251) million	1393 million	470 million
AMR	64.4 (33–110) million	21.7 (11.1–37.1) million	136 million	45 million
WPR	19.2 (6.5–40) million	6.6 (2.2–13.9) million	306 million	101 million
GLOBAL	**1807** (973–3181) **million**	**617** (330–1089) **million**	**3569 million**	**1165 million**

AMR: antimicrobial resistance; DDD: defined daily doses; UI: uncertainty interval; WHO: World Health Organization.

Regions: AFR: WHO African Region; AMR: WHO Region of the Americas; EMR: WHO Eastern Mediterranean Region; EUR: WHO European Region; SEAR: WHO South-East Asia Region; WPR: WHO Western Pacific Region.

1. Introduction | 2. Methodology | 3. Results by criterion | **4. Results by pathogen** | 5. Conclusions | 6. References

Impact on AMR by vaccine and region



Comparison of vaccine impact on AMR



Impact of pneumococcal vaccine on *prevalence* of non-susceptible invasive pneumococcal disease, USA



IPD: invasive pneumococcal disease; PCV: pneumococcal conjugate vaccine.

[a] Jansen KU, Knirsch C, Anderson AS. The role of vaccines in preventing bacterial antimicrobial resistance. Nat Med. 2018;24(1):10-9.

[b] Tomczyk S, Lynfield R, Schaffner W, Reingold A, Miller L, Petit S, et al. Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease with the 13-Valent Pneumococcal Conjugate Vaccine. Clin Infect Dis. 2016; 62(9).

PCV and rotavirus vaccines reduce *antibiotic use* in children in LMICs

Analysis of Demographic Health Surveys (DHS) and Multiple Indicator Cluster Surveys (MICS)

VACCINE IMPACT WITH RECENT COVERAGE

PCV prevents 23.8 million antibiotic treated episodes annually

Rotavirus vaccine prevents 13.7 million antibiotic treated episodes annually

VACCINE IMPACT WITH 90% COVERAGE

PCV could avert additional 21.7 million antibiotic treated episodes

Rotavirus vaccines could avert additional 18.3 million antibiotic treated episodes

Total PCV10/13 vaccine-preventable antibiotic consumption and incidence, children 24-59 months



Total rotavirus vaccine-preventable antibiotic consumption and incidence, children 0-23 months



https://www.nature.com/articles/s41586-020-2238-4

Maternal RSV vaccine impact on *antimicrobial prescribing*

Novavax vaccine trial conducted in 11 countries

Reduced antimicrobial prescriptions for ‘any diagnosis’ in infants born to mothers who received the RSV vaccine
Vaccine efficacy = 12.9%

Reduced antimicrobial prescriptions for ‘acute lower respiratory tract infections’
Vaccine efficacy= 16.9%

Over the first three months of infant’s life

Incidence of new antimicrobial prescription courses among infants



https://www.pnas.org/doi/10.1073/pnas.2112410119

Seasonal influenza vaccine impact on *antimicrobial prescribing*

Ecologic observational study, Canada (1997-2007)

Introduction of free seasonal influenza vaccine for those >6 mo, in 2000 (Ontario, Canada)

64% greater reduction in respiratory antibiotic prescriptions after universal vaccine introduction than status quo use

Reductions of secondary bacterial infections like pneumonia and otitis media

Association between influenza vaccination rate and rates of antibiotic prescription, Ontario, Canada



https://academic.oup.com/cid/article/49/5/750/308812

Bacterial vaccines in clinical and preclinical development 2021: clinical results

- **61 vaccines** in active clinical development identified (activity in the last 3 years, still list on company portfolio)
- **The highest number** of vaccine candidates for *S. pneumoniae*, TB, and *Shigella flexneri*
- **No candidates in clinical development**: *E. faecium*, *H. pylori*, *P. aeruginosa*, *A. baumannii*, *Enterobacter* spp, or *Campylobacter* spp.





How are vaccines integrated into global AMR strategies?

https://www.who.int/publications/i/item/9789241509763

https://www.who.int/publications/i/item/9789240082496

https://www.who.int/publications/m/item/global-research-agenda-for-antimicrobial-resistance-in-human-health

The Action Framework to leverage vaccines against AMR and AMU

Expanding use of licensed vaccines to maximize impact on AMR

Develop new vaccines that contribute to prevention and control of AMR

Expanding and sharing knowledge of vaccine impact on AMR



https://www.who.int/publications/m/item/leveraging-vaccines-to-reduce-antibiotic-use-and-prevent-antimicrobial-resistance

Conclusions

Vaccines have the potential to annually avert up to **515 000 deaths** and **US$ 30 billion in hospital costs** associated with AMR, and **2.5 billion antibiotic doses**.

The **impact of vaccines** in reducing AMR **needs to be recognized** by stakeholders in AMR and immunization. Global, regional and national AMR and immunization strategies and implementation frameworks **should include vaccines as interventions to reduce AMR**.

The **introduction of existing vaccines should be accelerated** and their **coverage increased**. All existing paediatric vaccines should reach the immunization targets of IA2030, and the use of vaccines in older age groups should be considered.

To prepare for the introduction of newly developed vaccines, the **impact of vaccines on AMR should be systematically evaluated** and embedded into existing decision frameworks.

To enable vaccine development, delivery and implementation to combat AMR, **include AMR endpoints in clinical trials**, develop **PPCs** for impactful vaccines, create **research roadmaps** for challenging vaccines.

Thank you